Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm

被引：98

作者：

Rao, Martin ^{[1
]}

Valentini, Davide ^{[1
,2
]}

Dodoo, Ernest ^{[1
,3
]}

Zumla, Alimuddin ^{[4
,5
]}

Maeurer, Markus ^{[1
,2
]}

机构：

[1] Karolinska Inst, Dept Lab Med LABMED, Div Therapeut Immunol TIM, Stockholm, Sweden

[2] Karolinska Univ Hosp Huddinge, Ctr Allogene Stem Cell Transplantat CAST, Stockholm, Sweden

[3] Karolinska Univ Hosp, Dept Neurosurg, Stockholm, Sweden

[4] UCL, Div Infect & Immun, London, England

[5] UCL Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England

来源：

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | 2017年 / 56卷

基金：

瑞典研究理事会;

关键词：

Anti-PD-1; Anti-PD-L1; T-cells; Cancer; Infectious disease; Host-directed therapy; T-CELL EXHAUSTION; LONG-TERM SAFETY; PD-1; EXPRESSION; PERIPHERAL-BLOOD; ANTI-PD-L1; ANTIBODY; IMMUNE CHECKPOINTS; PROGRAMMED DEATH-1; ADVANCED MELANOMA; CD70; MOLECULE PD-L1;

D O I：

10.1016/j.ijid.2017.01.028

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Objectives: Immune checkpoint pathways regulate optimal host immune responses against transformed cells, induce immunological memory, and limit tissue pathology. Conversely, aberrant immune checkpoint activity signifies a poor prognosis in cancer and infectious diseases. Host-directed therapy (HDT) via immune checkpoint blockade has revolutionized cancer treatment with therapeutic implications for chronic infections, thus laying the foundation for this review. Methods: Online literature searches were performed via PubMed, PubMed Central, and Google using the keywords "immune checkpoint inhibition"; "host-directed therapy"; "T cell exhaustion"; "cancer immunotherapy"; "anti-PD-1 therapy"; "anti-PD-L1 therapy"; "chronic infections"; "antigen-specific cells"; "tuberculosis"; "malaria"; "viral infections"; "human immunodeficiency virus"; "hepatitis B virus"; "hepatitis C virus"; "cytomegalovirus" and "Epstein-Barr virus". Search results were filtered based on relevance to the topics covered in this review. Results: The use of monoclonal antibodies directed against the antigen-experienced T-cell marker programmed cell death 1 (PD-1) and its ligand PD-L1 in the context of chronic infectious diseases is reviewed. The potential pitfalls and precautions, based on clinical experience from treating patients with cancer with PD-1/PD-L1 pathway inhibitors, are also described. Conclusions: Anti-PD-1/PD-L1 therapy holds promise as adjunctive therapy for chronic infectious diseases such as tuberculosis and HIV, and must therefore be tested in randomized clinical trials. (C) 2017 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

引用

页码：221 / 228

页数：8

共 99 条

[1] Distinct Effector Memory CD4+ T Cell Signatures in Latent Mycobacterium tuberculosis Infection, BCG Vaccination and Clinically Resolved Tuberculosis [J].

Adekambi, Toidi ;

Ibegbu, Chris C. ;

Kalokhe, Ameeta S. ;

Yu, Tianwei ;

Ray, Susan M. ;

Rengarajan, Jyothi .

PLOS ONE, 2012, 7 (04)

[2] Role Played by the Programmed Death-1-Programmed Death Ligand Pathway during Innate Immunity against Mycobacterium tuberculosis [J].

Alvarez, Ivana B. ;

Pasquinelli, Virginia ;

Jurado, Javier O. ;

Abbate, Eduardo ;

Musella, Rosa M. ;

de la Barrera, Silvia S. ;

Garcia, Veronica E. .

JOURNAL OF INFECTIOUS DISEASES, 2010, 202 (04) :524-532

[3]

[Anonymous], RES REV J ECOLOGY EN, DOI DOI 10.1145/2463209.2488734

[4] Phosphorylated STAT3 and PD-1 regulate IL-17 production and IL-23 receptor expression in Mycobacterium tuberculosis infection [J].

Bandaru, Anuradha ;

Devalraju, Kamakshi P. ;

Paidipally, Padmaja ;

Dhiman, Rohan ;

Venkatasubramanian, Sambasivan ;

Barnes, Peter F. ;

Vankayalapati, Ramakrishna ;

Valluri, Vijayalakshmi .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2014, 44 (07) :2013-2024

[5] Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies [J].

Borch, Troels H. ;

Donia, Marco ;

Andersen, Mads H. ;

Svane, Inge M. .

DRUG DISCOVERY TODAY, 2015, 20 (09) :1127-1134

[6] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[7] Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection [J].

Butler, Noah S. ;

Moebius, Jacqueline ;

Pewe, Lecia L. ;

Traore, Boubacar ;

Doumbo, Ogobara K. ;

Tygrett, Lorraine T. ;

Waldschmidt, Thomas J. ;

Crompton, Peter D. ;

Harty, John T. .

NATURE IMMUNOLOGY, 2012, 13 (02) :188-195

[8] SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation [J].

Chemnitz, JM ;

Parry, RV ;

Nichols, KE ;

June, CH ;

Riley, JL .

JOURNAL OF IMMUNOLOGY, 2004, 173 (02) :945-954

[9]

Cox AL, J EXP MED

[10] PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients [J].

D'Incecco, A. ;

Andreozzi, M. ;

Ludovini, V. ;

Rossi, E. ;

Capodanno, A. ;

Landi, L. ;

Tibaldi, C. ;

Minuti, G. ;

Salvini, J. ;

Coppi, E. ;

Chella, A. ;

Fontanini, G. ;

Filice, M. E. ;

Tornillo, L. ;

Incensati, R. M. ;

Sani, S. ;

Crino, L. ;

Terracciano, L. ;

Cappuzzo, F. .

BRITISH JOURNAL OF CANCER, 2015, 112 (01) :95-102

← 1 2 3 4 5 6 7 8 9 10 →